Lupin Q4FY23 Results: Consolidated PAT Rises to Rs 235.96 Cr

Lupin Q4FY23 Results: Consolidated PAT Rises to Rs 235.96 Cr

Lupin Limited. Q4 results show revenue fell from 4340.18 to 4467.35 crores, a 2.93% decrease in growth. EPS also dropped from ₹3.36 to ₹5.16, by 53.57%.

Let’s start with quarter and quarter bases first:

Lupin Company shared its Q4 results on Monday. They earned 4467.35 crores in revenue this quarter, but that’s less than the 450 crores they made last quarter. Unfortunately, the company’s growth decreased by 2.93 percent when comparing the two quarters.

In terms of profits, Lupin Ltd’s PAT (Profit After Tax) for this quarter was 235.96  crores, down from 153.47 crores in the previous quarter. Their quarter-to-quarter growth declined by 53.75 percent.

The company’s EPS (Earnings Per Share) this quarter is ₹5.16, which is a decrease of 53.57% from the ₹3.36 EPS in the previous quarter.

Also read:☞ ” Rain Industries Q4FY23 Results: Consolidated PAT Rises to Rs 105.37 Cr “

Now let’s discuss the results on a year-on-year basis:

The company made a total revenue of 16715.02 crores this year (2023), which is 1.01 percent higher than last year’s total revenue of 16547.17 crores.

This year’s PAT (Profit After Tax) is 430.08 crores, which is also 128.15% higher than last year’s PAT of 300 crores.

The EPS (Earnings Per Share) for this year is ₹9.41, which is 127.96% higher than the EPS of ₹-33.65 earned last year.

The company earns the most revenue from its retail and telecom segments, which are its two major revenue sources.

Lupin Share Dividend Announcement / Record Date:

The Board of Directors has declared a Final Dividend of ₹4 per Equity Share of Face Value of ₹2 each of the Company (200% of Face Value). Total Dividend for FY23 stood at ₹4 per Equity Share (Interim Dividend of ₹2 per Equity Share)

DividendRecord Date
₹4 per Equity ShareComing Soon

Dividend’s record date has not yet come

About Lupin:

Lupin Limited, headquartered in Mumbai, is an Indian multinational pharmaceutical company with a strong global presence and a significant revenue share in the generic pharmaceutical industry. The company’s primary therapeutic areas of interest comprise paediatrics, cardiovascular diseases, anti-infectives, diabetology, asthma, and anti-tuberculosis drugs.

Download Full PDF Q4 Results Lupin: Click Here

For More Latest News Click Here

One thought on “Lupin Q4FY23 Results: Consolidated PAT Rises to Rs 235.96 Cr

Leave a Reply

Your email address will not be published. Required fields are marked *